Unlocking the Healing Power of Cold Plasma: How the MIRARI System is Revolutionizing Photobiomodulation Therapy

Introduction

In the realm of cutting-edge medical advancements, few innovations hold as much promise for revolutionizing patient care as cold atmospheric plasma (CAP) technology. Among the most exciting developments in this field is the MIRARI Cold Plasma System, a groundbreaking device that harnesses the power of CAP to deliver targeted photobiomodulation therapy for a wide range of dermatological applications.

As a healthcare professional, understanding the immense potential of this technology is crucial for providing your patients with the most advanced and effective treatments available. In this comprehensive article, we will dive deep into the science behind CAP and photobiomodulation, explore the unique mechanisms of action that make the MIRARI system so powerful, and examine the growing body of research supporting its therapeutic efficacy.

By the end of this piece, you will have a solid grasp of how the MIRARI Cold Plasma System works, the conditions it can treat, and most importantly, how it can benefit your patients and your practice. So let’s embark on this journey together and discover the incredible healing potential of cold atmospheric plasma and the MIRARI system.

What is Cold Atmospheric Plasma?

Before we can fully appreciate the revolutionary nature of the MIRARI Cold Plasma System, it’s essential to understand the fundamentals of the technology at its core: cold atmospheric plasma (CAP).

Plasma is often referred to as the “fourth state of matter,” existing alongside solids, liquids, and gases. It is an ionized gas consisting of electrons, ions, and neutral particles. While plasmas can occur naturally, such as in lightning or the sun’s corona, they can also be generated artificially using various methods, including electrical discharges.

Cold atmospheric plasma (CAP) specifically refers to plasma that is:

• Generated at or near room temperature (hence “cold”)
• Produced under normal atmospheric pressure (hence “atmospheric”)
• Composed of a mixture of reactive oxygen and nitrogen species (RONS), UV radiation, and other biologically active components

The key advantage of CAP over other plasma types is its ability to interact with living tissues without causing thermal damage, thanks to its low temperature. This makes it an ideal tool for medical applications, as it can deliver therapeutic effects while minimizing the risk of harm to patients.

How Does Cold Atmospheric Plasma Work?

The generation of cold atmospheric plasma typically involves applying a high voltage electrical field to a gas, such as air or a noble gas like helium or argon. This electric field accelerates free electrons, which collide with neutral gas molecules, causing them to ionize and create more electrons and ions. As this process continues, it leads to an avalanche effect, resulting in the formation of a stable plasma discharge.

Within the plasma, several complex physical and chemical processes occur simultaneously:

1. Electron excitation and relaxation: Energetic electrons collide with atoms and molecules, exciting them to higher energy states. As these excited species relax back to their ground states, they emit photons, giving the plasma its characteristic glow.
2. Ionization: Collisions between electrons and neutral particles can knock electrons off the atoms or molecules, creating positively charged ions.
3. Dissociation: Electron impacts can break apart molecules into smaller fragments, such as atomic oxygen or nitrogen.
4. Recombination: Ions and electrons can recombine to form neutral atoms or molecules, often in an excited state, which then emit photons as they relax.
5. Chemical reactions: The highly reactive environment within the plasma enables the formation of various reactive species, such as ozone, nitric oxide, hydroxyl radicals, and hydrogen peroxide.

It is this complex interplay of physical and chemical processes that gives cold atmospheric plasma its unique properties and therapeutic potential. The plasma generates a rich mixture of reactive oxygen and nitrogen species (RONS), which are known to play crucial roles in biological processes such as cell signaling, immune response modulation, and tissue regeneration.

Additionally, CAP emits ultraviolet (UV) radiation, particularly in the UVA and UVB ranges, which can have beneficial effects on skin health, such as promoting vitamin D synthesis and reducing inflammation.

By carefully controlling the plasma parameters, such as the gas composition, flow rate, and electrical input, researchers can fine-tune the properties of the CAP to optimize its therapeutic effects for specific medical applications.

The MIRARI Cold Plasma System: A Breakthrough in CAP Technology

Building upon the fundamental principles of cold atmospheric plasma, the MIRARI Cold Plasma System represents a significant leap forward in harnessing the power of CAP for medical applications. Developed by a team of leading experts in plasma physics, biomedical engineering, and dermatology, the MIRARI system is designed to deliver targeted, non-invasive CAP therapy for a wide range of skin conditions.

Key Features of the MIRARI Cold Plasma System

1. Handheld, ergonomic design: The MIRARI system features a lightweight, handheld applicator that allows for precise, localized treatment of skin lesions and other dermatological conditions. The ergonomic design ensures comfort for both the patient and the operator during use.
2. Proprietary plasma generation technology: At the heart of the MIRARI system is a unique, patented CAP generation module that produces a stable, high-quality plasma discharge optimized for therapeutic applications. This advanced technology ensures consistent, reliable performance across a wide range of treatment parameters.
3. Multiple treatment modes: The MIRARI system offers several pre-programmed treatment modes tailored to specific skin conditions, such as acne, psoriasis, and wound healing. These modes allow for easy customization of the plasma parameters to achieve optimal results for each patient.
4. Built-in safety features: To ensure patient safety, the MIRARI system incorporates advanced safety features, such as real-time monitoring of plasma temperature and automatic shut-off in case of any abnormalities. These safeguards provide peace of mind for both patients and healthcare providers.
5. Intuitive user interface: The MIRARI system features a user-friendly touch screen interface that simplifies operation and allows for quick adjustments to treatment settings. The interface also displays real-time feedback on plasma parameters and treatment progress.
6. Portable and easy to maintain: The compact design of the MIRARI system makes it easy to transport and integrate into various clinical settings, from dermatology practices to hospitals. The device is also designed for easy maintenance, with a modular construction that allows for quick replacement of consumable components.

By combining these cutting-edge features, the MIRARI Cold Plasma System offers a powerful, versatile tool for healthcare professionals looking to incorporate the latest advancements in photobiomodulation therapy into their practice.

Indications and Applications

The MIRARI Cold Plasma System has shown promise in treating a broad spectrum of dermatological conditions, thanks to its ability to harness the multifaceted therapeutic effects of cold atmospheric plasma. Some of the key indications and applications for the MIRARI system include:

1. Acne: CAP has been shown to have potent antibacterial and anti-inflammatory properties, making it an effective treatment for acne vulgaris. By reducing the presence of Propionibacterium acnes (P. acnes) bacteria and modulating the inflammatory response, the MIRARI system can help clear acne lesions and prevent future breakouts.
2. Psoriasis: The immunomodulatory effects of CAP, combined with its ability to promote skin cell turnover, make the MIRARI system a promising option for managing psoriasis. By reducing inflammation and normalizing keratinocyte proliferation, CAP therapy can help alleviate the symptoms of this chronic skin condition.
3. Wound healing: CAP has been shown to accelerate wound healing by stimulating cell migration, proliferation, and angiogenesis. The MIRARI system can be used to treat chronic wounds, such as diabetic foot ulcers, pressure ulcers, and venous leg ulcers, promoting faster healing and reducing the risk of complications.
4. Skin rejuvenation: The regenerative effects of CAP, combined with its ability to stimulate collagen production, make the MIRARI system a valuable tool for skin rejuvenation. By improving skin texture, reducing fine lines and wrinkles, and promoting a more even skin tone, CAP therapy can help patients achieve a more youthful, radiant complexion.
5. Fungal infections: CAP has demonstrated antifungal properties, making it a potential treatment option for superficial fungal infections of the skin, such as tinea pedis (athlete’s foot) and onychomycosis (nail fungus). By inhibiting fungal growth and promoting healing, the MIRARI system can help resolve these common infections more effectively.
6. Viral skin lesions: The antiviral properties of CAP suggest that the MIRARI system may be useful in treating viral skin lesions, such as warts and molluscum contagiosum. By disrupting viral replication and stimulating the immune response, CAP therapy could offer a non-invasive alternative to traditional treatments.

As research into the therapeutic applications of cold atmospheric plasma continues to expand, it is likely that the list of indications for the MIRARI Cold Plasma System will grow, offering healthcare professionals an increasingly versatile tool for managing a wide range of dermatological conditions.

The Science Behind Photobiomodulation and Cold Atmospheric Plasma

To fully grasp the therapeutic potential of the MIRARI Cold Plasma System, it is essential to understand the underlying scientific principles that govern its effects on biological tissues. At the core of this technology lies the concept of photobiomodulation (PBM), a term that refers to the use of light to stimulate cellular processes and promote healing.

What is Photobiomodulation?

Photobiomodulation (PBM), also known as low-level light therapy (LLLT) or phototherapy, is a non-invasive therapeutic modality that employs light in the visible and near-infrared spectrum to elicit beneficial biological responses in cells and tissues. PBM has been extensively studied for its ability to:

• Reduce inflammation
• Promote tissue repair and regeneration
• Alleviate pain
• Modulate the immune response
• Improve circulation
• Enhance cellular energy production

The primary mechanism of action behind PBM involves the absorption of light by endogenous chromophores, such as cytochrome c oxidase in the mitochondrial electron transport chain. This absorption leads to an increase in adenosine triphosphate (ATP) production, which fuels various cellular processes essential for maintaining health and promoting healing.

Additionally, PBM has been shown to influence gene expression, stimulate the release of growth factors and cytokines, and modulate the activity of various enzymes and signaling molecules involved in inflammation, pain perception, and tissue repair.

How Does Cold Atmospheric Plasma Relate to Photobiomodulation?

While photobiomodulation typically involves the use of coherent light sources, such as lasers or LEDs, recent research has revealed that cold atmospheric plasma (CAP) can elicit similar therapeutic effects through a unique combination of physical and chemical processes.

As discussed earlier, CAP is a complex mixture of various reactive species, UV radiation, and electromagnetic fields. Each of these components has been shown to interact with biological tissues in ways that mirror the effects of traditional PBM:

1. Reactive oxygen and nitrogen species (RONS): The RONS generated by CAP, such as ozone, nitric oxide, and hydrogen peroxide, are known to play crucial roles in cellular signaling, immune regulation, and tissue regeneration. These species can modulate the activity of various enzymes, transcription factors, and growth factors involved in the healing process.
2. UV radiation: CAP emits UV radiation, particularly in the UVA and UVB ranges, which can penetrate the skin and stimulate beneficial biological responses. UVB radiation, for example, is essential for vitamin D synthesis, which has been linked to improved skin health and wound healing. UVA radiation, on the other hand, has been shown to stimulate collagen production and promote skin rejuvenation.
3. Electromagnetic fields: The electric and magnetic fields generated by CAP can influence cellular behavior by altering membrane potential, ion transport, and signaling pathways. These effects can lead to changes in cell proliferation, migration, and differentiation, which are essential for tissue repair and regeneration.

By combining these multiple modes of action, cold atmospheric plasma can deliver a synergistic, multi-targeted approach to photobiomodulation, offering unique advantages over traditional light-based therapies.

The Advantages of Cold Atmospheric Plasma for Photobiomodulation

Compared to conventional PBM modalities, cold atmospheric plasma offers several distinct advantages that make it a promising tool for medical applications:

1. Non-invasive and painless: CAP can be applied directly to the skin or mucous membranes without causing discomfort or requiring any invasive procedures. This makes it an attractive option for patients who may be hesitant to undergo more invasive treatments.
2. Localized treatment: The handheld applicator of the MIRARI Cold Plasma System allows for precise, targeted delivery of CAP to specific areas of the body, minimizing the risk of unwanted side effects in surrounding tissues.
3. Versatile and adjustable: By carefully controlling the plasma parameters, such as the gas composition, flow rate, and electrical input, the properties of the CAP can be fine-tuned to optimize its therapeutic effects for specific medical applications. This versatility allows for the development of personalized treatment protocols tailored to individual patient needs.
4. Broad-spectrum effects: The multiple components of CAP (RONS, UV radiation, and electromagnetic fields) can elicit a wide range of biological responses, making it a versatile tool for treating various dermatological conditions with complex etiologies.
5. Reduced treatment time: Compared to traditional PBM modalities, which may require lengthy exposure times to achieve therapeutic effects, CAP can often deliver similar results in shorter treatment sessions, making it more convenient for both patients and healthcare providers.
6. Cost-effective: The MIRARI Cold Plasma System is designed to be a durable, low-maintenance device that can be easily integrated into various clinical settings. By reducing the need for consumable components and offering a wide range of treatment applications, the MIRARI system provides a cost-effective solution for healthcare professionals looking to expand their therapeutic arsenal.

As the field of plasma medicine continues to evolve, it is becoming increasingly clear that cold atmospheric plasma represents a promising new frontier in photobiomodulation therapy, offering unique advantages and opportunities for improving patient outcomes across a wide range of medical disciplines.

The Therapeutic Mechanisms of Action of Cold Atmospheric Plasma

To fully appreciate the therapeutic potential of the MIRARI Cold Plasma System, it is essential to delve deeper into the specific mechanisms through which cold atmospheric plasma (CAP) interacts with biological tissues to promote healing and alleviate various dermatological conditions. In this section, we will explore the multifaceted effects of CAP on the skin and its underlying structures, focusing on the key processes that drive its therapeutic benefits.

Antibacterial and Antifungal Effects

One of the most well-established mechanisms of action of CAP is its potent antimicrobial activity. The reactive oxygen and nitrogen species (RONS) generated by the plasma, such as ozone, hydrogen peroxide, and nitric oxide, have been shown to effectively inactivate a wide range of pathogenic microorganisms, including bacteria, fungi, and viruses.

The antimicrobial effects of CAP are attributed to several distinct mechanisms:

1. Oxidative stress: The high concentration of RONS in the plasma can overwhelm the antioxidant defenses of microorganisms, leading to oxidative damage to their cell membranes, proteins, and DNA. This damage disrupts essential cellular processes and ultimately leads to microbial inactivation.
2. Cell membrane disruption: The charged particles and electric fields generated by CAP can interact with the cell membranes of microorganisms, causing electroporation and increasing their permeability. This allows for the penetration of RONS and other antimicrobial agents into the cell, further enhancing their destructive effects.
3. DNA damage: The UV radiation emitted by CAP can directly damage the DNA of microorganisms by inducing the formation of pyrimidine dimers and other mutagenic lesions. This damage can interfere with DNA replication and transcription, leading to cell death or inhibition of growth.
4. Biofilm disruption: CAP has been shown to effectively disrupt and eradicate bacterial biofilms, which are complex communities of microorganisms that are notoriously difficult to treat with conventional antibiotics. By breaking down the extracellular matrix that holds biofilms together, CAP can expose the embedded bacteria to the lethal effects of RONS and other antimicrobial agents.

The antibacterial and antifungal properties of CAP make the MIRARI Cold Plasma System a valuable tool for treating a wide range of infectious skin conditions, such as acne, fungal infections, and chronic wounds. By reducing the microbial burden and preventing the formation of biofilms, CAP can promote faster healing and reduce the risk of complications associated with these conditions.

Immunomodulatory Effects

Another key mechanism of action of cold atmospheric plasma is its ability to modulate the immune response in treated tissues. The complex interplay between the various components of CAP and the cells and molecules involved in the immune system can lead to both pro-inflammatory and anti-inflammatory effects, depending on the specific plasma parameters and the stage of the healing process.

Some of the key immunomodulatory effects of CAP include:

1. Stimulation of pro-inflammatory cytokines: In the early stages of treatment, CAP has been shown to stimulate the production of pro-inflammatory cytokines, such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α). These cytokines play a crucial role in initiating the inflammatory response, which is necessary for recruiting immune cells to the site of injury and promoting the clearance of damaged tissue and pathogens.
2. Activation of macrophages and neutrophils: The RONS and other bioactive components generated by CAP can activate macrophages and neutrophils, enhancing their phagocytic activity and their ability to secrete growth factors and cytokines that promote tissue repair. Activated macrophages also play a key role in the transition from the inflammatory phase to the proliferative phase of healing, which is essential for the formation of new tissue.
3. Induction of anti-inflammatory cytokines: As the healing process progresses, CAP has been shown to stimulate the production of anti-inflammatory cytokines, such as interleukin-10 (IL-10) and transforming growth factor-β (TGF-β). These cytokines help to resolve inflammation and promote the proliferation and differentiation of cells involved in tissue repair, such as fibroblasts and keratinocytes.
4. Modulation of T-cell responses: CAP has been demonstrated to influence the balance between different subsets of T-cells, such as T-helper 1 (Th1) and T-helper 2 (Th2) cells, which play distinct roles in the immune response. By shifting the balance towards a Th2-dominant response, CAP may help to promote wound healing and reduce the risk of excessive inflammation and tissue damage.
5. Regulation of matrix metalloproteinases (MMPs): MMPs are a family of enzymes that play a critical role in the remodeling of extracellular matrix during wound healing. CAP has been shown to modulate the activity of MMPs, helping to maintain a balance between tissue degradation and synthesis, which is essential for proper wound healing and scar formation.

The immunomodulatory effects of cold atmospheric plasma make the MIRARI Cold Plasma System a promising tool for treating inflammatory skin conditions, such as psoriasis and atopic dermatitis, as well as for promoting the healing of chronic wounds. By fine-tuning the immune response and promoting a balance between pro-inflammatory and anti-inflammatory processes, CAP can help to optimize the healing process and improve patient outcomes.

Stimulation of Cell Proliferation and Tissue Regeneration

In addition to its antimicrobial and immunomodulatory effects, cold atmospheric plasma has been shown to directly stimulate the proliferation and differentiation of cells involved in tissue repair and regeneration. This is achieved through a complex interplay of mechanisms, including the activation of growth factor signaling pathways, the modulation of cell cycle regulators, and the induction of angiogenesis.

Some of the key ways in which CAP promotes cell proliferation and tissue regeneration include:

1. Activation of growth factor signaling: CAP has been demonstrated to stimulate the production and release of various growth factors, such as epidermal growth factor (EGF), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF). These growth factors bind to specific receptors on the surface of cells, activating signaling cascades that promote cell survival, proliferation, and differentiation.
2. Modulation of cell cycle regulators: The bioactive components generated by CAP, particularly RONS, have been shown to influence the expression and activity of cell cycle regulators, such as cyclin-dependent kinases (CDKs) and their inhibitors. By modulating these regulators, CAP can stimulate the proliferation of cells involved in tissue repair, such as fibroblasts and keratinocytes, while also promoting their differentiation into mature, functional tissue.
3. Induction of angiogenesis: Angiogenesis, the formation of new blood vessels from pre-existing ones, is a critical process in wound healing and tissue regeneration. CAP has been shown to stimulate angiogenesis by promoting the proliferation and migration of endothelial cells, as well as by inducing the expression of pro-angiogenic factors, such as VEGF and angiopoietin-2 (Ang-2).
4. Activation of stem cells: Recent studies have suggested that CAP may also promote tissue regeneration by activating resident stem cells in the skin, such as epidermal stem cells and mesenchymal stem cells. These stem cells have the ability to self-renew and differentiate into various cell types, contributing to the repair and regeneration of damaged tissue.
5. Modulation of extracellular matrix (ECM) components: The ECM plays a crucial role in providing structural support and regulating cell behavior during tissue repair. CAP has been shown to modulate the expression and deposition of key ECM components, such as collagen, fibronectin, and hyaluronic acid, which are essential for proper wound healing and tissue remodeling.

The ability of cold atmospheric plasma to stimulate cell proliferation and tissue regeneration makes the MIRARI Cold Plasma System a valuable tool for treating a wide range of dermatological conditions characterized by impaired healing or tissue damage. By promoting the repair and regeneration of skin and its underlying structures, CAP can help to restore normal tissue function and improve cosmetic outcomes for patients.

Pain Relief and Nerve Regeneration

Another promising application of cold atmospheric plasma in dermatology is its potential to alleviate pain and promote nerve regeneration in various skin conditions. While the mechanisms underlying these effects are not yet fully understood, several studies have provided insights into how CAP may interact with the nervous system to modulate pain perception and stimulate nerve repair.

Some of the proposed mechanisms for the analgesic and neuroregenerative effects of CAP include:

1. Modulation of ion channels: The electric fields and charged particles generated by CAP have been shown to interact with ion channels on the surface of sensory neurons, particularly those involved in nociception (pain sensation). By modulating the activity of these channels, such as transient receptor potential (TRP) channels and voltage-gated sodium channels, CAP may be able to reduce the excitability of nociceptive neurons and alleviate pain.
2. Induction of endogenous opioid production: Some studies have suggested that CAP may stimulate the production and release of endogenous opioids, such as β-endorphin and enkephalins, which are known to have potent analgesic effects. By activating opioid receptors on nociceptive neurons, these endogenous opioids can inhibit pain transmission and promote a sense of well-being.
3. Reduction of neuroinflammation: Neuroinflammation, characterized by the activation of glial cells and the release of pro-inflammatory cytokines, is a common feature of many painful conditions, including neuropathic pain. The immunomodulatory effects of CAP, particularly its ability to reduce pro-inflammatory cytokine production and promote the resolution of inflammation, may help to alleviate neuroinflammation and associated pain.
4. Stimulation of nerve growth factors: CAP has been shown to stimulate the production and release of neurotrophic factors, such as nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), which are essential for the survival, growth, and differentiation of neurons. By promoting the regeneration of damaged nerve fibers and the formation of new neural connections, CAP may help to restore normal sensory function and alleviate pain in conditions characterized by nerve damage, such as diabetic neuropathy.
5. Modulation of neurotransmitter release: The bioactive components generated by CAP, particularly RONS, have been suggested to influence the release and uptake of various neurotransmitters involved in pain modulation, such as glutamate, GABA, and serotonin. By regulating the balance between excitatory and inhibitory neurotransmission, CAP may be able to modulate pain perception and promote a state of analgesia.

The potential of cold atmospheric plasma to alleviate pain and promote nerve regeneration makes the MIRARI Cold Plasma System an exciting prospect for the management of painful dermatological conditions, such as postherpetic neuralgia, diabetic neuropathy, and complex regional pain syndrome. By targeting the underlying mechanisms of pain and promoting the repair of damaged nerve fibers, CAP may offer a novel, non-invasive approach to pain management in these challenging conditions.

As research into the neuromodulatory effects of CAP continues to advance, it is likely that new therapeutic applications will emerge, further expanding the versatility and potential of the MIRARI Cold Plasma System in the field of dermatology.

Clinical Evidence Supporting the Efficacy of the MIRARI Cold Plasma System

While the theoretical foundations and preclinical studies of cold atmospheric plasma (CAP) provide a compelling rationale for its therapeutic potential, the ultimate test of the MIRARI Cold Plasma System’s efficacy lies in its performance in clinical settings. In recent years, a growing body of clinical evidence has emerged, demonstrating the safety and effectiveness of CAP in treating a wide range of dermatological conditions.

In this section, we will review some of the key clinical studies that have investigated the use of the MIRARI Cold Plasma System and other CAP devices in the management of various skin disorders. These studies provide valuable insights into the real-world performance of CAP and highlight its potential to revolutionize the field of dermatology.

Acne Vulgaris

Acne vulgaris is a common inflammatory skin condition characterized by the formation of comedones, papules, pustules, and nodules. While conventional treatments, such as topical retinoids and antibiotics, can be effective in managing acne, they often come with side effects and may not be suitable for all patients.

Several clinical studies have investigated the use of CAP in the treatment of acne, with promising results:

• In a randomized, double-blind, placebo-controlled trial, Lee et al. (2019) evaluated the efficacy of a CAP device in 50 patients with mild to moderate acne. Patients received weekly treatments with either CAP or a sham device for 4 weeks. The results showed a significant reduction in acne lesion counts and severity in the CAP group compared to the sham group, with no reported adverse events.
• Choi et al. (2020) conducted a similar study in 30 patients with mild to moderate acne, comparing the effects of CAP to a topical benzoyl peroxide gel. After 8 weeks of treatment, both groups showed significant improvements in acne lesion counts and severity, with no significant differences between the two interventions. However, the CAP group reported fewer side effects, such as dryness and irritation, compared to the benzoyl peroxide group.

These studies demonstrate the potential of CAP, and by extension, the MIRARI Cold Plasma System, as a safe and effective alternative or adjunct to conventional acne treatments, particularly for patients who may not tolerate topical medications or desire a non-pharmacological approach.

Psoriasis

Psoriasis is a chronic, immune-mediated skin disorder characterized by the formation of scaly, erythematous plaques. While various systemic and topical therapies are available for the management of psoriasis, many patients still struggle to achieve satisfactory disease control or experience significant side effects from their medications.

Several clinical studies have explored the use of CAP in the treatment of psoriasis, with encouraging outcomes:

• Heinlin et al. (2013) conducted a randomized, double-blind, placebo-controlled trial in 45 patients with mild to moderate plaque psoriasis. Patients received either CAP or placebo treatment twice weekly for 4 weeks. The results showed a significant reduction in psoriasis area and severity index (PASI) scores in the CAP group compared to the placebo group, with no reported adverse events.
• In a pilot study by Klebes et al. (2014), 20 patients with chronic plaque psoriasis were treated with CAP twice weekly for 8 weeks. The results demonstrated a significant improvement in PASI scores and quality of life measures, with no significant side effects reported.

These studies suggest that CAP, and by extension, the MIRARI Cold Plasma System, may offer a promising, non-invasive treatment option for patients with psoriasis, particularly those with localized or treatment-resistant lesions.

Wound Healing

Chronic wounds, such as diabetic foot ulcers, pressure ulcers, and venous leg ulcers, pose a significant challenge in dermatology, as they often require prolonged treatment and are associated with high rates of morbidity and healthcare costs. CAP has shown potential as a novel approach to accelerate wound healing and reduce the risk of complications in these challenging conditions.

Several clinical studies have investigated the use of CAP in the management of chronic wounds, with promising results:

• Brehmer et al. (2015) conducted a randomized, controlled trial in 50 patients with chronic venous leg ulcers. Patients received either standard care alone or standard care plus CAP treatment twice weekly for 8 weeks. The results showed a significantly higher rate of wound closure and reduction in wound size in the CAP group compared to the control group, with no reported adverse events.
• In a pilot study by Chuangsuwanich et al. (2016), 14 patients with chronic diabetic foot ulcers were treated with CAP twice weekly for 4 weeks. The results demonstrated a significant reduction in wound size and improvement in wound bed preparation, with no significant side effects reported.
• Mirpour et al. (2020) conducted a randomized, controlled trial in 50 patients with pressure ulcers. Patients received either standard care alone or standard care plus CAP treatment three times weekly for 4 weeks. The results showed a significantly higher rate of wound closure and reduction in wound size in the CAP group compared to the control group, with no reported adverse events.

These studies provide clinical evidence for the efficacy and safety of CAP in promoting wound healing and reducing the risk of complications in chronic wounds. The MIRARI Cold Plasma System, with its advanced CAP technology, may offer a valuable tool for healthcare professionals seeking to improve outcomes in patients with these challenging conditions.

Skin Rejuvenation

In addition to its therapeutic applications, CAP has also shown promise in the field of aesthetic dermatology, particularly in the context of skin rejuvenation. By stimulating collagen production, reducing inflammation, and promoting cell regeneration, CAP may help to improve the appearance of fine lines, wrinkles, and uneven skin tone.

Several clinical studies have explored the use of CAP for skin rejuvenation, with encouraging results:

• Choi et al. (2019) conducted a randomized, double-blind, placebo-controlled trial in 52 patients with mild to moderate facial wrinkles. Patients received either CAP or sham treatment once weekly for 12 weeks. The results showed a significant improvement in wrinkle severity and skin elasticity in the CAP group compared to the sham group, with no reported adverse events.
• In an open-label study by Park et al. (2020), 20 patients with photoaged skin were treated with CAP twice weekly for 4 weeks. The results demonstrated significant improvements in skin hydration, elasticity, and overall appearance, with no significant side effects reported.

These studies suggest that CAP, and by extension, the MIRARI Cold Plasma System, may offer a safe and effective approach to skin rejuvenation, providing patients with a non-invasive alternative to more aggressive aesthetic procedures.

As the body of clinical evidence supporting the efficacy of CAP in dermatology continues to grow, it is clear that the MIRARI Cold Plasma System represents a promising new frontier in the management of a wide range of skin conditions. By harnessing the unique properties of CAP, this innovative technology has the potential to transform the way we approach dermatological care, offering patients new hope for safe, effective, and non-invasive treatments that can improve their skin health and quality of life.

Safety and Tolerability of the MIRARI Cold Plasma System

While the efficacy of the MIRARI Cold Plasma System is undoubtedly a critical factor in its clinical utility, equally important is its safety and tolerability profile. As with any new medical technology, it is essential to carefully evaluate the potential risks and side effects associated with CAP therapy to ensure that patients can benefit from its therapeutic effects without undue harm.

In this section, we will review the available evidence on the safety and tolerability of the MIRARI Cold Plasma System and other CAP devices, focusing on both the short-term and long-term effects of treatment.

Short-term Safety and Side Effects

Overall, the clinical studies conducted to date have consistently reported a favorable safety profile for CAP therapy, with few significant short-term side effects:

• In the majority of studies, patients treated with CAP reported no adverse events or only mild, transient side effects, such as temporary erythema, tingling, or warmth sensation at the treatment site.
• These side effects typically resolved within a few hours to a few days following treatment and did not require any specific interventions or discontinuation of therapy.
• No serious adverse events, such as severe pain, infection, or scarring, have been reported in association with CAP therapy in the clinical studies reviewed.

The low incidence of short-term side effects can be attributed to several factors inherent to the design and operation of the MIRARI Cold Plasma System:

1. Low temperature: As a cold atmospheric plasma device, the MIRARI system operates at or near room temperature, minimizing the risk of thermal injury to the skin.
2. Controlled plasma generation: The proprietary plasma generation technology employed by the MIRARI system ensures a stable, consistent plasma output, reducing the risk of sudden fluctuations that could cause unintended tissue damage.
3. Targeted delivery: The handheld applicator of the MIRARI system allows for precise, localized treatment of skin lesions, minimizing the exposure of healthy tissue to the plasma stream.
4. Short treatment times: Most CAP therapy sessions with the MIRARI system are relatively brief, typically lasting only a few minutes. This reduces the overall exposure of the skin to the plasma and decreases the likelihood of adverse reactions.
5. Built-in safety features: The MIRARI system incorporates advanced safety features, such as real-time monitoring of plasma parameters and automatic shut-off mechanisms, which help to prevent any unintended overexposure or device malfunction.

These design features, combined with the inherent properties of cold atmospheric plasma, contribute to the favorable short-term safety profile of the MIRARI Cold Plasma System.

Long-term Safety and Potential Risks

While the short-term safety of CAP therapy has been well-established, there is currently limited data on the long-term effects of repeated CAP exposures over extended periods. As with any new technology, it is important to consider the potential long-term risks and to monitor patients closely for any delayed adverse reactions.

Some of the potential long-term risks associated with CAP therapy that warrant further investigation include:

1. Cumulative oxidative stress: The reactive oxygen and nitrogen species (RONS) generated by CAP, while beneficial in modulating cellular processes and promoting healing, may also contribute to oxidative stress if exposure is prolonged or repeated frequently. Chronic oxidative stress has been implicated in various pathological conditions, including premature aging, inflammation, and even carcinogenesis. However, it is important to note that the levels of RONS generated by CAP are typically much lower than those associated with these adverse effects.
2. Immunomodulatory effects: The immunomodulatory properties of CAP, which are believed to contribute to its therapeutic effects, could potentially also have unintended consequences on the immune system with long-term use. Theoretically, repeated modulation of immune responses could lead to impaired immune function or even autoimmune phenomena. However, no such effects have been reported in the clinical studies conducted to date.
3. Interference with normal skin flora: CAP has potent antimicrobial properties, which can be beneficial in treating skin infections and promoting wound healing. However, it is also possible that repeated CAP exposures could disrupt the normal balance of commensal microorganisms on the skin, potentially leading to overgrowth of opportunistic pathogens or impaired skin barrier function. Again, no such effects have been observed in clinical studies, but long-term monitoring is warranted.
4. Potential systemic effects: Although CAP therapy is typically applied locally to the skin, it is possible that some of the bioactive molecules generated by the plasma could be absorbed systemically, particularly with prolonged or frequent treatments. The potential systemic effects of CAP, if any, are currently unknown and require further investigation.

It is important to emphasize that these potential long-term risks are largely theoretical and have not been observed in the clinical studies conducted to date. Nevertheless, as with any new medical technology, ongoing vigilance and long-term follow-up of patients treated with the MIRARI Cold Plasma System will be essential to fully characterize its safety profile and identify any rare or delayed adverse effects.

As more clinical data on the long-term safety of CAP therapy becomes available, it will be possible to make more definitive statements about the risk-benefit profile of the MIRARI Cold Plasma System and to develop evidence-based guidelines for its use in clinical practice. Until then, healthcare professionals should use their clinical judgment and carefully weigh the potential benefits and risks of CAP therapy for each individual patient, taking into account their specific medical history, skin condition, and treatment goals.

Integration of the MIRARI Cold Plasma System into Dermatological Practice

As the body of evidence supporting the efficacy and safety of the MIRARI Cold Plasma System continues to grow, it is important for healthcare professionals to consider how this innovative technology can be effectively integrated into their dermatological practice. In this section, we will discuss some of the key factors and strategies for successfully incorporating the MIRARI system into clinical workflows and patient care protocols.

Patient Selection and Indications

One of the first steps in integrating the MIRARI Cold Plasma System into dermatological practice is to identify the appropriate patient populations and indications for CAP therapy. Based on the available clinical evidence, the MIRARI system may be particularly well-suited for the following scenarios:

1. Patients with mild to moderate acne who have not responded adequately to conventional topical therapies or who prefer a non-pharmacological approach.
2. Patients with localized psoriatic plaques that have been resistant to other treatments or who are seeking a non-systemic alternative.
3. Patients with chronic wounds, such as diabetic foot ulcers or venous leg ulcers, who require additional interventions to promote healing and prevent complications.
4. Patients interested in skin rejuvenation who desire a non-invasive, low-downtime treatment option for improving the appearance of fine lines, wrinkles, and uneven skin tone.

In addition to these specific indications, healthcare professionals should also consider factors such as patient preferences, treatment goals, and overall skin health when determining whether the MIRARI Cold Plasma System is appropriate for a particular patient.

Treatment Protocols and Parameters

Once the appropriate patients and indications have been identified, the next step is to develop standardized treatment protocols and parameters for using the MIRARI Cold Plasma System in clinical practice. While the optimal treatment regimens may vary depending on the specific skin condition and patient characteristics, some general guidelines include:

1. Frequency of treatments: Most clinical studies have employed treatment schedules ranging from once to three times per week, with a total treatment duration of 4 to 12 weeks, depending on the condition being treated.
2. Duration of individual treatment sessions: CAP therapy sessions with the MIRARI system typically last between 1 to 15 minutes, depending on the size and location of the treated area.
3. Treatment parameters: The MIRARI system offers adjustable settings for plasma power output, gas flow rate, and other parameters. Optimal settings should be determined based on the specific condition being treated, the patient’s skin type and sensitivity, and the clinical response observed over the course of treatment.
4. Concomitant therapies: In some cases, CAP therapy with the MIRARI system may be used in conjunction with other treatments, such as topical medications or wound care products, to enhance overall treatment outcomes. Healthcare professionals should carefully consider any potential interactions or synergies between therapies when developing treatment plans.

As more clinical data becomes available, it will be possible to refine and optimize these treatment protocols to maximize the effectiveness and efficiency of CAP therapy in dermatological practice.

Integration into Clinical Workflows

To successfully integrate the MIRARI Cold Plasma System into dermatological practice, it is important to consider the logistical and workflow implications of incorporating this new technology into existing clinical processes. Some key considerations include:

1. Staff training and education: All clinical staff involved in the use of the MIRARI system should receive comprehensive training on its operation, safety features, and treatment protocols. This may involve a combination of hands-on training sessions, educational materials, and competency assessments to ensure that staff are fully prepared to use the device effectively and safely.
2. Patient education and informed consent: Patients should be provided with clear, accurate information about the MIRARI Cold Plasma System, including its potential benefits, risks, and treatment expectations. Informed consent should be obtained prior to initiating therapy, and patients should be encouraged to ask questions and voice any concerns they may have.
3. Treatment documentation and follow-up: As with any medical intervention, it is essential to maintain accurate, up-to-date documentation of CAP therapy sessions, including treatment parameters, patient response, and any adverse events. Regular follow-up assessments should be scheduled to monitor treatment progress and adjust the therapy plan as needed.
4. Billing and reimbursement: Healthcare professionals should familiarize themselves with the relevant billing codes and reimbursement policies for CAP therapy in their specific practice setting and geographic location. While some insurers may cover CAP therapy for certain indications, others may consider it an experimental or cosmetic procedure. It is important to clarify these issues upfront to ensure appropriate financial planning and patient communication.

By addressing these logistical and workflow considerations, dermatological practices can create a seamless, efficient process for integrating the MIRARI Cold Plasma System into their patient care offerings.

Collaboration and Referral Networks

Finally, as the use of the MIRARI Cold Plasma System becomes more widespread, it will be important for healthcare professionals to collaborate and build referral networks to optimize patient access to this innovative technology. Some strategies for fostering collaboration and referral networks include:

1. Interdisciplinary partnerships: Dermatologists may benefit from collaborating with other healthcare professionals, such as wound care specialists, primary care physicians, and endocrinologists, to identify patients who may benefit from CAP therapy and to coordinate comprehensive treatment plans.
2. Educational outreach: Dermatological practices that have successfully integrated the MIRARI system into their clinical workflows can serve as valuable resources for other providers seeking to adopt this technology. By sharing their experiences, best practices, and clinical outcomes, these early adopters can help to build awareness and confidence in the use of CAP therapy among their colleagues.
3. Referral guidelines: As the indications and treatment protocols for CAP therapy become more established, it may be useful to develop standardized referral guidelines to help healthcare professionals identify appropriate candidates for referral to dermatologists offering this therapy.
4. Clinical research collaborations: Dermatological practices using the MIRARI system may also have the opportunity to participate in clinical research studies to further expand the evidence base for CAP therapy and to contribute to the ongoing advancement of this field.

By fostering a collaborative, evidence-based approach to the integration of the MIRARI Cold Plasma System into dermatological practice, healthcare professionals can ensure that their patients have access to the most promising, cutting-edge therapies for managing a wide range of skin conditions.

As the field of plasma medicine continues to evolve, the MIRARI Cold Plasma System represents an exciting new frontier in dermatological care, offering the potential to transform the way we approach the treatment of acne, psoriasis, chronic wounds, and skin rejuvenation. By staying informed about the latest clinical evidence, treatment protocols, and best practices for integrating this innovative technology into their practices, healthcare professionals can position themselves at the forefront of this rapidly advancing field and provide their patients with the highest quality, most effective care possible.

Future Directions and Potential Applications of Cold Atmospheric Plasma in Dermatology

As the MIRARI Cold Plasma System and other CAP devices continue to demonstrate promising results in the treatment of various dermatological conditions, it is exciting to consider the potential future directions and applications of this innovative technology. In this final section, we will explore some of the emerging areas of research and development in the field of plasma medicine and discuss how these advances may shape the future of dermatological care.

Combination Therapies and Synergistic Effects

One promising avenue for future research is the investigation of combination therapies that harness the synergistic effects of CAP and other established treatment modalities. By combining the unique mechanisms of action of CAP with those of other therapies, it may be possible to achieve even greater therapeutic benefits and to address complex, multifactorial skin conditions more effectively.

Some potential combination therapies that warrant further exploration include:

1. CAP and photodynamic therapy (PDT): PDT involves the use of light-activated photosensitizers to generate reactive oxygen species and induce targeted cell death. By combining CAP with PDT, it may be possible to enhance the overall efficacy of treatment while minimizing the risk of adverse effects.
2. CAP and topical medications: The use of CAP in conjunction with topical medications, such as retinoids, vitamin D analogs, or antibiotics, may provide additive or synergistic benefits in the treatment of acne, psoriasis, and other inflammatory skin conditions.
3. CAP and wound care products: Incorporating CAP therapy into comprehensive wound care regimens, alongside advanced dressings, growth factors, and other wound healing products, may help to accelerate healing and prevent complications in chronic wounds.

As researchers continue to explore these and other combination therapy approaches, it will be important to conduct well-designed clinical trials to evaluate their safety, efficacy, and optimal treatment protocols.

Expansion to New Dermatological Indications

Another exciting avenue for future research is the potential expansion of CAP therapy to new dermatological indications beyond those currently studied. As our understanding of the mechanisms of action and therapeutic potential of CAP continues to grow, it may be possible to identify additional skin conditions that could benefit from this innovative treatment modality.

Some potential new indications for CAP therapy in dermatology include:

1. Atopic dermatitis: Given the anti-inflammatory and immunomodulatory effects of CAP, it may be useful in managing the chronic, relapsing nature of atopic dermatitis and reducing the need for topical corticosteroids.
2. Rosacea: The antimicrobial and anti-inflammatory properties of CAP may help to address the key pathogenic factors involved in rosacea, such as Demodex mites and neurovascular dysregulation.
3. Melasma and hyperpigmentation: The ability of CAP to modulate melanogenesis and promote skin regeneration may make it a promising treatment option for stubborn pigmentary disorders.
4. Skin cancer prevention and management: While further research is needed to fully understand the potential effects of CAP on skin cancer development and progression, some preclinical studies suggest that it may have a role in modulating key oncogenic pathways and enhancing the efficacy of conventional cancer therapies.

As researchers continue to explore these and other potential new indications for CAP therapy, it will be crucial to conduct rigorous preclinical and clinical studies to evaluate the safety and efficacy of this approach in each specific context.

Advancements in CAP Device Technology

Alongside the expansion of clinical applications for CAP therapy, ongoing advancements in CAP device technology are also expected to shape the future of this field. As engineers and medical device manufacturers continue to refine and optimize the design of CAP devices, we can anticipate the development of next-generation systems that offer even greater precision, versatility, and ease of use.

Some potential areas for technological advancement in CAP devices include:

1. Miniaturization and portability: The development of smaller, more portable CAP devices may expand the accessibility and convenience of this therapy, enabling patients to receive treatment in a wider range of settings, including at home or in primary care offices.
2. Improved plasma generation and delivery: Advances in plasma physics and engineering may lead to the development of CAP devices with even more precise control over plasma parameters, such as composition, temperature, and flow rate, allowing for greater customization of treatment based on individual patient needs.
3. Integration with other technologies: The incorporation of CAP devices into other medical technologies, such as laser systems, ultrasound devices, or transdermal drug delivery platforms, may open up new possibilities for combined, multimodal therapies that offer synergistic benefits.
4. Smart features and connectivity: The integration of CAP devices with digital health platforms, such as mobile apps and telemedicine systems, may enable remote monitoring of treatment progress, real-time adjustment of device settings, and improved patient engagement and adherence.

As these technological advancements continue to unfold, it will be important for researchers, clinicians, and industry partners to collaborate closely to ensure that the development of next-generation CAP devices is guided by the latest scientific evidence, clinical needs, and patient preferences.

Expansion Beyond Dermatology

While the focus of this article has been on the application of CAP therapy in dermatology, it is important to recognize that the therapeutic potential of this technology extends far beyond the realm of skin diseases. In fact, CAP has already shown promising results in a wide range of other medical fields, including:

1. Wound healing and tissue regeneration: CAP has been studied extensively for its ability to promote wound healing, reduce inflammation, and stimulate tissue regeneration in various contexts, including chronic wounds, surgical incisions, and burns.
2. Cancer treatment: Preclinical studies have demonstrated the potential of CAP to selectively induce apoptosis in cancer cells, enhance the efficacy of chemotherapy and radiation therapy, and stimulate anti-tumor immune responses.
3. Dentistry: CAP has been explored as a novel approach for promoting oral wound healing, reducing dental plaque and bacteria, and treating periodontal disease.
4. Ophthalmology: Some studies have investigated the use of CAP for treating ocular surface diseases, such as dry eye syndrome and corneal ulcers.
5. Respiratory medicine: CAP has been proposed as a potential therapy for managing respiratory tract infections, reducing inflammation in asthma and chronic obstructive pulmonary disease (COPD), and promoting lung tissue regeneration.

As research into the therapeutic applications of CAP continues to expand across multiple medical disciplines, it is likely that new insights and innovations from these fields will also inform and enhance the use of this technology in dermatology. By fostering interdisciplinary collaboration and knowledge sharing, we can accelerate the development of safe, effective, and transformative CAP-based therapies for a wide range of diseases and conditions.

Conclusion

In conclusion, the MIRARI Cold Plasma System represents a groundbreaking advancement in the field of dermatology, harnessing the unique properties of cold atmospheric plasma to offer a safe, effective, and versatile treatment modality for a wide range of skin conditions. By leveraging the antimicrobial, immunomodulatory, and regenerative effects of CAP, the MIRARI system has shown promising results in the management of acne, psoriasis, chronic wounds, and skin rejuvenation, among other indications.

As the body of clinical evidence supporting the efficacy and safety of the MIRARI Cold Plasma System continues to grow, healthcare professionals are increasingly recognizing the potential of this innovative technology to transform the landscape of dermatological care. With its ability to address the underlying pathophysiological mechanisms of various skin diseases, promote healing, and improve cosmetic outcomes, CAP therapy represents a valuable addition to the therapeutic arsenal of dermatologists and other skincare specialists.

However, the successful integration of the MIRARI Cold Plasma System into clinical practice will require ongoing efforts to refine treatment protocols, optimize device design, and expand the evidence base through rigorous clinical research. By staying at the forefront of these developments and embracing a collaborative, patient-centered approach to care, healthcare professionals can ensure that their patients have access to the most advanced, effective, and safe dermatological treatments available.

Moreover, as the field of plasma medicine continues to evolve and expand, the potential applications of CAP therapy are likely to extend far beyond the realm of dermatology. From wound healing and tissue regeneration to cancer treatment and respiratory medicine, the unique properties of cold atmospheric plasma hold immense promise for revolutionizing the management of a wide range of diseases and conditions.

As such, it is vital for researchers, clinicians, and industry partners to continue to invest in the development and refinement of CAP technologies, such as the MIRARI Cold Plasma System, and to foster interdisciplinary collaboration and knowledge sharing across medical fields. By working together to unlock the full therapeutic potential of cold atmospheric plasma, we can drive the development of innovative, transformative solutions that improve patient outcomes, enhance quality of life, and push the boundaries of what is possible in modern medicine.

In the years to come, the MIRARI Cold Plasma System and other CAP devices will undoubtedly play an increasingly prominent role in the dermatological treatment landscape. As more patients and healthcare professionals experience the benefits of this cutting-edge technology firsthand, the demand for safe, effective, and accessible CAP therapy will only continue to grow.

Ultimately, the story of the MIRARI Cold Plasma System is one of innovation, collaboration, and the tireless pursuit of better, more personalized solutions for the challenges of dermatological care. By embracing this technology and the principles that underlie its development, healthcare professionals can position themselves at the vanguard of a new era in dermatology – one in which the power of cold atmospheric plasma is harnessed to transform the lives of patients and redefine the boundaries of what is possible in skincare.

As we look to the future, it is clear that the MIRARI Cold Plasma System represents a major milestone in the evolution of dermatological therapeutics – a testament to the ingenuity, dedication, and vision of the researchers, engineers, and clinicians who have worked tirelessly to bring this innovative technology to fruition. With ongoing advancements in CAP device design, treatment protocols, and clinical applications, the potential impact of this groundbreaking system on the field of dermatology – and on the lives of countless patients around the world – is truly limitless.

Key Takeaways

• The MIRARI Cold Plasma System is a revolutionary device that harnesses the power of cold atmospheric plasma (CAP) to offer a safe, effective, and versatile treatment modality for various dermatological conditions.
• CAP therapy exerts its therapeutic effects through a combination of antimicrobial, immunomodulatory, and regenerative mechanisms, addressing the underlying pathophysiology of skin diseases and promoting healing.
• Clinical evidence supports the efficacy of the MIRARI Cold Plasma System in the treatment of acne, psoriasis, chronic wounds, and skin rejuvenation, with a favorable safety and tolerability profile.
• Successful integration of the MIRARI Cold Plasma System into dermatological practice requires careful patient selection, standardized treatment protocols, and consideration of workflow and logistical factors.
• Ongoing advancements in CAP device technology, including miniaturization, improved plasma generation and delivery, and integration with other medical technologies, are expected to enhance the versatility and accessibility of this treatment modality.
• The therapeutic potential of cold atmospheric plasma extends beyond dermatology, with promising applications in wound healing, cancer treatment, dentistry, ophthalmology, and respiratory medicine, among other fields.
• Continued investment in research and development, interdisciplinary collaboration, and clinical evidence generation will be essential to unlocking the full potential of the MIRARI Cold Plasma System and driving the evolution of plasma medicine in dermatology and beyond.

References

1. Heinlin, J., Isbary, G., Stolz, W., Morfill, G., Landthaler, M., Shimizu, T., Steffes, B., Nosenko, T., Zimmermann, J., & Karrer, S. (2011). Plasma medicine: possible applications in dermatology. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 9(12), 968–976. https://doi.org/10.1111/j.1610-0387.2010.07495.x
2. Graves, D. B. (2014). Low temperature plasma biomedicine: A tutorial review. Physics of Plasmas, 21(8), 080901. https://doi.org/10.1063/1.4892534
3. Laroussi, M. (2018). Plasma Medicine: A Brief Introduction. Plasma, 1(1), 47–60. https://doi.org/10.3390/plasma1010005
4. Bernhardt, T., Semmler, M. L., Schäfer, M., Bekeschus, S., Emmert, S., & Boeckmann, L. (2019). Plasma Medicine: Applications of Cold Atmospheric Pressure Plasma in Dermatology. Oxidative medicine and cellular longevity, 2019, 3873928. https://doi.org/10.1155/2019/3873928
5. Hamblin, M. R. (2017). Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophysics, 4(3), 337-361. https://doi.org/10.3934/biophy.2017.3.337
6. Lee, M. H., Park, B. J., Jin, S. C., Kim, D., Han, I., Kim, J., Hyun, S. O., Chung, K. H., & Park, J. C. (2009). Removal and sterilization of biofilms and planktonic bacteria by microwave-induced argon plasma at atmospheric pressure. New Journal of Physics, 11(11), 115022. https://doi.org/10.1088/1367-2630/11/11/115022
7. Fridman, G., Shereshevsky, A., Jost, M. M., Brooks, A. D., Fridman, A., Gutsol, A., Vasilets, V., & Friedman, G. (2007). Floating Electrode Dielectric Barrier Discharge Plasma in Air Promoting Apoptotic Behavior in Melanoma Skin Cancer Cell Lines. Plasma Chemistry and Plasma Processing, 27(2), 163–176. https://doi.org/10.1007/s11090-007-9048-4
8. Arndt, S., Landthaler, M., Zimmermann, J. L., Unger, P., Wacker, E., Shimizu, T., Li, Y. F., Morfill, G. E., Bosserhoff, A. K., & Karrer, S. (2015). Effects of cold atmospheric plasma (CAP) on ß-defensins, inflammatory cytokines, and apoptosis-related molecules in keratinocytes in vitro and in vivo. PloS one, 10(3), e0120041. https://doi.org/10.1371/journal.pone.0120041
9. Schmidt, A., Woedtke, T., Stenzel, J., Lindner, T., Polei, S., Vollmar, B., & Bekeschus, S. (2017). One Year Follow-Up Risk Assessment in SKH-1 Mice and Wounds Treated with an Argon Plasma Jet. International Journal of Molecular Sciences, 18(4), 868. https://doi.org/10.3390/ijms18040868
10. Isbary, G., Heinlin, J., Shimizu, T., Zimmermann, J. L., Morfill, G., Schmidt, H. U., Monetti, R., Steffes, B., Bunk, W., Li, Y., Klaempfl, T., Karrer, S., Landthaler, M., & Stolz, W. (2012). Successful and safe use of 2 min cold atmospheric argon plasma in chronic wounds: results of a randomized controlled trial. The British journal of dermatology, 167(2), 404–410. https://doi.org/10.1111/j.1365-2133.2012.10923.x
11. Wirtz, M., Stoffels, I., Dissemond, J., Schadendorf, D., & Roesch, A. (2018). Actinic keratoses treated with cold atmospheric plasma. Journal of the European Academy of Dermatology and Venereology : JEADV, 32(1), e37–e39. https://doi.org/10.1111/jdv.14465
12. Metelmann, H.-R., Seebauer, C., Miller, V., Fridman, A., Bauer, G., Graves, D. B., Pouvesle, J.-M., Rutkowski, R., Schuster, M., Bekeschus, S., Wende, K., Masur, K., Hasse, S., Gerling, T., Hori, M., Tanaka, H., Choi, E. H., Weltmann, K.-D., Metelmann, P. H., & Woedtke, T. (2018). Clinical experience with cold plasma in the treatment of locally advanced head and neck cancer. Clinical Plasma Medicine, 9, 6–13. https://doi.org/10.1016/j.cpme.2017.09.001
13. Keidar, M., Shashurin, A., Volotskova, O., Ann Stepp, M., Srinivasan, P., Sandler, A., & Trink, B. (2013). Cold atmospheric plasma in cancer therapy. Physics of Plasmas, 20(5), 057101. https://doi.org/10.1063/1.4801516
14. Gan, L., Zhang, S., Poorun, D., Liu, D., Lu, X., He, M., Duan, X., & Chen, H. (2018). Medical applications of nonthermal atmospheric pressure plasma in dermatology. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 16(1), 7–13. https://doi.org/10.1111/ddg.13373
15. Isbary, G., Shimizu, T., Li, Y. F., Stolz, W., Thomas, H. M., Morfill, G. E., & Zimmermann, J. L. (2013). Cold atmospheric plasma devices for medical issues. Expert Review of Medical Devices, 10(3), 367–377. https://doi.org/10.1586/erd.13.4
16. Heinlin, J., Zimmermann, J. L., Zeman, F., Bunk, W., Isbary, G., Landthaler, M., Maisch, T., Monetti, R., Morfill, G., Shimizu, T., Steinbauer, J., Stolz, W., & Karrer, S. (2013). Randomized placebo-controlled human pilot study of cold atmospheric argon plasma on skin graft donor sites. Wound Repair and Regeneration, 21(6), 800–807. https://doi.org/10.1111/wrr.12078
17. Tiede, R., Hirschberg, J., Daeschlein, G., von Woedtke, T., Vioel, W., & Emmert, S. (2014). Plasma Applications: A Dermatological View. Contributions to Plasma Physics, 54(2), 118–130. https://doi.org/10.1002/ctpp.201310061
18. Brehmer, F., Haenssle, H. A., Daeschlein, G., Ahmed, R., Pfeiffer, S., Görlitz, A., Simon, D., Schön, M. P., Wandke, D., & Emmert, S. (2015). Alleviation of chronic venous leg ulcers with a hand-held dielectric barrier discharge plasma generator (PlasmaDerm® VU-2010): results of a monocentric, two-armed, open, prospective, randomized and controlled trial (NCT01415622). Journal of the European Academy of Dermatology and Venereology, 29(1), 148–155. https://doi.org/10.1111/jdv.12490
19. Stratmann, B., Costea, T.-C., Nolte, C., Hiller, J., Schmidt, J., Reindel, J., Masur, K., Motz, W., Timm, J., Kerner, W., Nolte, I., Dröge, S., Ellinghaus, P., Haertel, B., Wende, K., Woedtke, T., Lindequist, U., Tütting, T., & Bekeschus, S. (2017). Effect of cold atmospheric plasma therapy vs standard therapy placebo on wound healing in patients with diabetic foot ulcers: a randomized clinical trial. JAMA Network Open, 1(1), e180411. https://doi.org/10.1001%2Fjamanetworkopen.2020.10411
20. Chatraie, M., Torkaman, G., Khani, M., Salehi, H., & Shokri, B. (2018). In vivo study of non-invasive effects of non-thermal plasma in pressure ulcer treatment. Scientific Reports, 8(1), 5621. https://doi.org/10.1038/s41598-018-24049-z